MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.42
-0.69
-1.21%
After Hours: 56.44 +0.02 +0.04% 18:15 01/17 EST
OPEN
57.69
PREV CLOSE
57.11
HIGH
57.69
LOW
56.11
VOLUME
1.54M
TURNOVER
--
52 WEEK HIGH
73.72
52 WEEK LOW
12.51
MARKET CAP
5.65B
P/E (TTM)
81.16
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARWR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARWR News

  • SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  • PR Newswire.2d ago
  • Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference
  • Investor's Business Daily.01/11 13:00
  • Here's Why Arrowhead Pharmaceuticals Stock Soared 410% in 2019
  • MotleyFool.com.01/09 17:08
  • Buy Arrowhead Pharmaceuticals Now At Near The Institutional Discount
  • Seeking Alpha - Article.01/08 21:50

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ARWR

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More

Webull offers Arrowhead Pharmaceuticals Inc (ARWR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.